Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group | Zendy

Amit M. Oza | Zendy; Laurie Elit | Zendy; MingSound Tsao | Zendy; Suzanne KamelReid | Zendy; Jim Biagi | Zendy; Diane Provencher | Zendy; Walter H. Gotlieb | Zendy; Paul Hoskins | Zendy; Prafull Ghatage | Zendy; Katia Tonkin | Zendy; Helen Mackay | Zendy; J. Mazurka | Zendy; Joana Sederias | Zendy; Percy Ivy | Zendy; Janet Dancey | Zendy; Elizabeth A. Eisenhauer | Zendy

Open Access

Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

Author(s) -

Amit M. Oza,

Laurie Elit,

MingSound Tsao,

Suzanne KamelReid,

Jim Biagi,

Diane Provencher,

Walter H. Gotlieb,

Paul Hoskins,

Prafull Ghatage,

Katia Tonkin,

Helen Mackay,

J. Mazurka,

Joana Sederias,

Percy Ivy,

Janet Dancey,

Elizabeth A. Eisenhauer

Publication year - 2011

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2010.34.1578

Subject(s) - temsirolimus , pten , medicine , endometrial cancer , chemotherapy , progressive disease , oncology , pi3k/akt/mtor pathway , tensin , cancer , response evaluation criteria in solid tumors , gastroenterology , cancer research , biology , signal transduction , discovery and development of mtor inhibitors , biochemistry

Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene, and loss of function mutations are common and appear to be important in the pathogenesis of endometrial carcinomas. Loss of PTEN causes deregulated phosphatidylinositol-3 kinase/serine-threonine kinase/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling which may provide neoplastic cells with a selective survival advantage by enhancing angiogenesis, protein translation, and cell cycle progression. Temsirolimus, an ester derivative of rapamycin that inhibits mTOR, was evaluated in this setting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research